Venetoclax + Rituximab (VenR), 24-month fixed-duration (MURANO schedule)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-VENETOCLAX DRUG-RITUXIMAB DRUG-ALLOPURINOL |
|---|
| ID | REG-VENETOCLAX-RITUXIMAB |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-CLL-2024 SRC-NCCN-BCELL-2025 |
Notes
MURANO trial (Seymour 2018; updated 2023): in r/r CLL after ≥1 prior line, VenR vs BR — superior 4-year PFS (57.3% vs 4.6%) AND superior 4-year OS (85% vs 67%, HR 0.41). Approved 2L+ for r/r CLL. 24-month fixed-duration with deep MRD-negative responses (~62% MRD-negative at end of treatment). Distinct from VenO (1L CLL14 schedule, 12 mo + obinutuzumab anti-CD20 instead of rituximab). TLS PROTOCOL CRITICAL: skipping ramp = fatal hyperkalemia + AKI.
Used By
Indication
IND-CLL-2L-VENR-MURANO- IND-CLL-2L-VENR-MURANO